

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 297445 Garcinia 8300+ Complex

ARTG entry for Medicine Listed

Sponsor Herbs of Gold Pty Ltd

Postal Address PO Box 3143, KIRRAWEE, NSW, 2232

Australia

ARTG Start Date 12/12/2017

Product Category Medicine

Status Active

Approval Area Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Garcinia 8300+ Complex

Product Type Single Medicine Product Effective Date 5/09/2019

Permitted Indications

Aids/assists abdominal fat loss

Maintain/support abdominal fat loss

Reduce/decrease/supress hunger/appetite

Traditionally used in Indian/Siddha medicine to reduce/decrease/supress hunger/appetite

Aid/assist/helps glucose/sugar/carbohydrate metabolism

Helps maintain/support cellular uptake of (state vitamin/mineral/nutrient)

Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)

Indication Requirements

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to eating disorders.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Page 1 of 2

Australian Government

Department of Health

Therapeutic Goods Administration

| | ngs |
|--|-----|
| | |
| | |

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

Caralluma adscendens var. fimbriata herb Extract dry concentrate 333.33 mg

Equivalent: Caralluma adscendens var. fimbriata (Dry) 4 g

chromic chloride hexahydrate171.19 microgramEquivalent: chromium33.4 microgram

chromium picolinate 134.11 microgram
Equivalent: chromium 16.6 microgram

Equivalent: chromium 16.6 microgram

Citrus aurantium fruit Extract dry concentrate standardised 166.67 mg

Equivalent: Citrus aurantium (Dry)

Garcinia gummi-gutta fruit peel Extract dry concentrate standardised

Equivalent: Garcinia gummi-gutta (Dry)

8.33 g

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate

Carnauba Wax

colloidal anhydrous silica croscarmellose sodium

crospovidone hypromellose

macrogol 400

magnesium stearate

maize starch

microcrystalline cellulose

povidone

titanium dioxide

[©] Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.